go to main content
Research Radboud technology centers Radboud Biobank News New Automated PBMC isolation method introduced in LMI
21 September 2021

The Radboud Biobank (RB) and the laboratory of Medical Immunology (LMI) are making plans to replace the density gradient centrifugation method with a new automated PBMC isolation method, the AutoMACS Pro Separator.

In summary, the yield of PBMCs after isolation with the AutoMACS procedure was similar or greater in comparison to the density gradient procedure, while viability and the phenotypic distribution after both isolation procedures was comparable.

All studies that collect PBMCs have already been informed by mail and after agreement the RB will plan a start date with LMI, a new SOP will be written and coupled to the samples in the RB.  For more information or questions on this new PBMC isolation method contact the Radboud Biobank.

 

  • Want to know more about these subjects? Click on the buttons below for more news.

    Radboud Biobank

Related news items

Patient must give explicit consent Request for permission to use medical data, leftover human biomaterial and images

8 April 2022 read more

MyCoS sub-biobank

8 April 2022

The Radboud Biobank has added one new sub-biobank to the collection: MyCoS.

read more

Dutch-Nordic Alliance for Precision Cancer Medicine launched

26 November 2021

The Nordic countries (Denmark, Sweden, Norway, and Finland) are together setting up national clinical precision cancer trials modelled on the very successful DRUP trial in the Netherlands.

read more

Health-RI, geared up to accelerate

21 September 2021

The Dutch cabinet has selected Health-RI's National Growth Fund proposal for a national health data infrastructure. On 5 October, the kick-off will take place during a live meeting in Jaarbeurs Media Plaza in Utrecht.

read more

SUNRISE-CRC sub-biobank

21 September 2021

The main purpose of SUNRISE-CRC is to determine whether treatment with a high dose of sunitinib provides a better chance of survival and slows the progression of (colo)rectal cancer (CRC) more than standard treatment with TAS-102.

read more

PRECISE sub-biobank

21 September 2021

The aim of the PRECISE biobank is to develop the first, smart multi-modal liquid biopsy test service for the prediction of immune checkpoint inhibitor response in urothelial cancer (UC) patients – the PRECISE IVD.

read more